Literature DB >> 32637916

Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests.

Saniye Gİrİt1, Ayşe Ayzit Atabek2, Ebru Şenol3, Tuba KoÇkar Kizilirmak4, Sevgi Pekcan5, Şafak GÖktaŞ6, Sedat Öktem4, Özgür KasapÇopur7, Haluk ÇokuĞraŞ2.   

Abstract

OBJECTIVES: This study aims to analyze the coherence between T-SPOT tuberculosis test (T-SPOT.TB) and tuberculin skin test (TST) with different cut-off values in screening latent tuberculosis infection (LTBI) both prior to and at the sixth month of anti-tumor necrosis factor (anti-TNF) treatment. PATIENTS AND METHODS: This prospective multicentric study included 57 children (34 girls, 23 boys, mean age 12.4±3.9 years; range, 6 to 18 years) diagnosed with immune-mediated inflammatory diseases (IMIDs) evaluated with TST and T-SPOT.TB for screening LTBI both prior to and at the sixth month of treatment with anti-TNF agents. Coherence between two tests was analyzed for TST cut-off values suggested by the local guidelines and also for different possible cut-off values of TST.
RESULTS: Tuberculin skin test was positive (≥5 mm) in 28.1% (n=16) of patients in the screening prior to treatment and in 33.3% (n=19) at the sixth month of treatment. T-SPOT.TB test was positive in 8.8% (n=5) of patients both prior to and at the sixth month of treatment. Coherence between two tests was poor or fair when compared with all possible TST cut-off values both prior to and at the sixth month of anti-TNF therapy.
CONCLUSION: Our results show poor coherence between T-SPOT.TB and TST for all possible cut-off values of TST. Thus, using both tests would be beneficial in screening LTBI until further studies bring new evidence on the subject.
Copyright © 2020, Turkish League Against Rheumatism.

Entities:  

Keywords:  Child; immune system disease; interferon-gamma release assay; latent tuberculosis; tuberculin skin test

Year:  2019        PMID: 32637916      PMCID: PMC7322294          DOI: 10.5606/ArchRheumatol.2020.7294

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  31 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis.

Authors:  Cláudia Diniz Lopes Marques; Ângela Luzia Branco Pinto Duarte; Virginia Maria Barros de Lorena; Joelma Rodrigues Souza; Wayner Vieira Souza; Yara de Miranda Gomes; Eduardo Maia Freese de Carvalho
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

3.  EULAR recommendations for vaccination in paediatric patients with rheumatic diseases.

Authors:  M W Heijstek; L M Ott de Bruin; M Bijl; R Borrow; F van der Klis; I Koné-Paut; A Fasth; K Minden; A Ravelli; M Abinun; G S Pileggi; M Borte; N M Wulffraat
Journal:  Ann Rheum Dis       Date:  2011-08-03       Impact factor: 19.103

4.  Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.

Authors:  Gerald H Mazurek; John Jereb; Andrew Vernon; Phillip LoBue; Stefan Goldberg; Kenneth Castro
Journal:  MMWR Recomm Rep       Date:  2010-06-25

Review 5.  The tuberculin skin test.

Authors:  R E Huebner; M F Schein; J B Bass
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

6.  Comparing the tuberculin skin test and T-SPOT.TB blood test in children.

Authors:  Andrea T Cruz; Abby M Geltemeyer; Jeffrey R Starke; Jaime A Flores; Edward A Graviss; Kim C Smith
Journal:  Pediatrics       Date:  2010-12-06       Impact factor: 7.124

7.  Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.

Authors:  David M Lewinsohn; Michael K Leonard; Philip A LoBue; David L Cohn; Charles L Daley; Ed Desmond; Joseph Keane; Deborah A Lewinsohn; Ann M Loeffler; Gerald H Mazurek; Richard J O'Brien; Madhukar Pai; Luca Richeldi; Max Salfinger; Thomas M Shinnick; Timothy R Sterling; David M Warshauer; Gail L Woods
Journal:  Clin Infect Dis       Date:  2016-12-08       Impact factor: 9.079

8.  Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers.

Authors:  N Cobanoglu; U Ozcelik; U Kalyoncu; S Ozen; S Kiraz; N Gurcan; M Kaplan; D Dogru; E Yalcin; S Pekcan; M Kose; R Topaloglu; N Besbas; A Bakkaloglu; N Kiper
Journal:  Int J Tuberc Lung Dis       Date:  2007-11       Impact factor: 2.373

9.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103

10.  Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines.

Authors:  Tasnim Hasan; Eric Au; Sharon Chen; Allison Tong; Germaine Wong
Journal:  BMJ Open       Date:  2018-09-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.